research Updates From 2021 Virtual Dermatology Nurses' Association Convention
The convention discussed various skin conditions, treatments, and the importance of continuous learning in dermatology nursing.
Search
for
Sort by
Research
60-90 / 423 resultsresearch Consensus on the Treatment of Alopecia Areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Androgenetic Alopecia – Update 2022
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Alopecia Areata in Latin America: Where Are We and Where Are We Going?
Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Discovery Of A Novel And Highly Selective JAK3 Inhibitor As A Potent Hair Growth Promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Novel TMEM173 Mutation and the Role of Disease-Modifying Alleles
A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
research Scarring Hair Follicle Destruction Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research Sterol Intermediates of Cholesterol Biosynthesis Inhibit Hair Growth and Trigger an Innate Immune Response in Cicatricial Alopecia
Cholesterol-related compounds can stop hair growth and cause inflammation in a type of scarring hair loss.
research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Alopecia Areata: Current Understanding and Management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution, And Tumor-Initiating Cells
Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
research Ruxolitinib Protects Skin Stem Cells And Maintains Skin Homeostasis In Murine Graft-Versus-Host Disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research Efficacy of Tofacitinib in Treatment of Alopecia Universalis in Two Patients
Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.